Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Scott Martin, Ph.D., Group Lead, Functional Genomics, Genentech Inc

#personalizedmedicine

#oncology

#Boston

#immunology

#biotech

#CRSPR

#geneediting

#genomics

@CHI

@genentech

@Boston

@BiotechNews

@pharma_BI

@AVIVA_1950

@GeneEditing

@Genomeresearch

Scott Martin, Ph.D., Group Lead, Functional Genomics, Genentech Inc.

#CRSPR

#Cas9

#geneediting

#genomics

Ralph Garippa, Ph.D., Director, RNAi & Gene Editing Core Facility, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center

#CRSPR

#Cas9

#geneediting

#genomics

@Boston

@BiotechNews

@pharma_BI

@AVIVA_1950

James Inglese, Ph.D., Head Assay Development & Screening Technologies, National Center for Advancing Translational Sciences, National Institutes of Health

#raredisease

#genetics

#AssayDevelopment

#NIH

#CMT

#drugdiscovery

@NIH

@BiotechNews

@PharmaNews

@pharma_BI

@AVIVA_1950

@DrugDiscover365

10:40

11:40

Namjin Chung, Ph.D., Head, Functional Genomics Platform, Discovery Research, AbbVie, Inc.

10:40 Vignettes From the Bench: CRISPR Engineering Lymphoma Lines

Arthur L. Shaffer, III, Ph.D., Staff Scientist, Laboratory of Dr. Louis Staudt, Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health

11:10 PANEL DISCUSSION: Will Interference from CRISPR Silence RNAi?

Moderator: Scott Martin, Ph.D., Group Lead, Functional Genomics, Genentech Inc.

#CRISPR

#Cas9

#NIH

#CMT

#drugdiscovery

#pharmanews

#CRSPR

#genomics

@abbvie

@BiotechNews

@PharmaNews

@pharma_BI

@AVIVA_1950

@DrugDiscover365

1:50 PM

2:20

2:50

1:40 Chairperson’s Opening Remarks

James Inglese, Ph.D., Head Assay Development & Screening Technologies, National Center for Advancing Translational Sciences, National Institutes of Health

1:50 MicroRNA Target Site Editing of Chondrocyte Master-Regulators in Primary Human Cells Using CRISPR-Cas9

Christine Seidl, Ph.D., Post-Doctoral Research Associate, Cell Signaling, Kennedy Institute of Rheumatology, Oxford University

2:20 Massively Parallel Combinatorial Genetic Perturbation Screening with CRISPR-Cas9 in Human Cells

Cheryl H. Cui, Ph.D. Candidate, Harvard-MIT Division of Health Science and Technology, MIT

2:50 The Scientist’s Guide to CRISPR Law

Paul Enríquez, J.D., LL.M., Ph.D. Candidate, Structural and Molecular Biochemistry, North Carolina State University

#CMT

#inflammation

#systembiology

#genetics

@NIH

@UniofOxford

@MIT

@Harvard

@NCarolinaSt

3:30-6 PM

SC7: Using IP Landscape Studies to Improve Your Confidence While Navigating a Crowded IP and Technology Space – Detailed Agenda

Instructors:

David Berry, M.D., Ph.D., General Partner, Flagship Ventures

Ananda Chakrabarty, Ph.D., Department of Microbiology & Immunology, University of Illinois College of Medicine

Anu Daniel, Ph.D., Licensing Manager, Innovation, Partners Healthcare

Drew Lowery, Ph.D., Director of Life Sciences and Group Leader, Biotechnology Pharmaceuticals Group, Global Prior Art, Inc.

Amy Mendel, J.D., SVP, Intellectual Property, Evelo Biosciences

Daniel Neuman, Ph.D., Group Leader, Chemistry & Materials, Global Prior Art, Inc.

SC12: Introduction to Gene Editing – Detailed Agenda

Instructors:

Stephanie Mohr, Ph.D., Lecturer, Genetics & Director, Drosophila RNAi Screening Center at Harvard Medical School

Claire Yanhui Hu, Ph.D., Senior Bioinformatician, Drosophila RNAi Screening Center, Department of Genetics, Harvard Medical School

Paul Enríquez, J.D., LL.M., Ph.D. Candidate, Structural and Molecular Biochemistry, North Carolina State University

#patent

#partnership

#innovation

#biotech

#genetics

#CRSPR

#Cas9

#molecularscreen

@PartnersNews

@GlobalArtAgency

@harvardmed

@NCarolinaSt

GENOME EDITING FOR IN VIVO APPLICATIONS

Bryan R. Cullen, Ph.D., James B. Duke Professor of Molecular Genetics and Microbiology and Director, Center for Virology, Duke University

#virology

#adenovirus

10:35 AM

11:05 AM

11:35 AM

James Wilson, M.D., Ph.D., Professor, Department of Pathology and Laboratory Medicine, Perelman School of Medicine; Director, Orphan Disease Center and Director, Gene Therapy Program, University of Pennsylvania

10:35 Targeted Endonucleases as Antiviral Agents: Promises and Pitfalls

Keith R. Jerome, M.D., Ph.D., Member, Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center; Professor and Head, Virology Division, Department of Laboratory Medicine, University of Washington

11:05 Nucleic Acid Delivery Systems for RNA Therapy and Gene Editing

Daniel Anderson, Ph.D., Professor, Department of Chemical Engineering, Institute for Medical Engineering & Science, Harvard-MIT Division of Health Sciences & Technology and David H. Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology

11:35 PANEL DISCUSSION: CRISPR/Cas: A Realistic and Practical Look at What the Future Could Hold

Moderator: Bryan R. Cullen, Ph.D., James B. Duke Professor of Molecular Genetics and Microbiology and Director, Center for Virology, Duke University

Participants: Session Speakers

#virology

#drugdelivery

#genedelivery

#cancer

@UW

@MIT

@kochinstitute

@Duke

12:45 PM

Simone T. Sredni, M.D., Ph.D., Research Assistant Professor, Neurological Surgery, Northwestern University Feinberg School of Medicine, Ann and Robert H. Lurie Children’s Hospital of Chicago

12:45 Luncheon Presentation: Building a Better Research Story: Screening with shRNA and CRISPR

Ryan Raver, Ph.D., Global Product Manager, Functional Genomics, MilliporeSigma

#kinome

#brain

#ChildhoodCancerAwareness

#genomics

@MilliporeSigma

COMPLEMENTING THE USE CRISPR & RNAi FOR DISEASE MODELING

2:15 PM

2:45 PM

3:15 PM

4:25 PM

4:55 PM

Ralph Garippa, Ph.D., Director, RNAi Core Facility, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center

2:15 Comparing Arrayed siRNA and CRISPR Approaches Towards Functional Genomics Screening

Scott Martin, Ph.D., Group Lead, Functional Genomics, Genentech Inc.

2:45 Use of CRISPR/Cas9-Based Gene Editing to Model and Treat Retinal Degenerative Disease

Donald Zack, M.D., Ph.D., Guerrieri Professor of Genetic Engineering and Molecular Ophthalmology, Johns Hopkins University

3:15 HP Inkjet Technology for Enhancing Gene Editing Experiments

Erica Squires, Ph.D., Senior Applications Scientist, HP Inc.

4:25 Harnessing the Versatile CRISPR-Cas9 Systems for Cancer Modeling Platforms

Geoffrey Bartholomeusz, Ph.D., Associate Professor and Director, Target Identification and Validation Program, Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center

4:55 Technology Panel: Trends in CRISPR & RNAi Technologies

Moderator: Ralph Garippa, Ph.D., Director, RNAi Core Facility, Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center

Panelists:

Louise Baskin, Senior Product Manager, Dharmacon, GE Healthcare

Paul Diehl, Ph.D., Director, Business Development, Cellecta Inc.

#eyedisease

#bioprinting

#3D_printing

#tech

#innovation

#geneediting

#endcancer

#cancer

#drugdiscovery

@MSKCC_OncoNotes

@genentech

@MacularHope

@HopkinsMedicine

@HP

@My3DPrinting

@MDAndersonNews

@MMSK

@sloan_kettering

@CELLECTA

8:00 AM

8:10 AM

8:40 AM

9:10 AM

10:25 AM

10:55 AM

TJ Cradick , Ph.D., Head of Genome Editing, CRISPR Therapeutics

8:10 Functional Genomics Using CRISPR-Cas9: Technology and Applications

Neville Sanjana, Ph.D., Core Faculty Member, New York Genome Center and Assistant Professor, Department of Biology & Center for Genomics and Systems Biology, New York University

8:40 Therapeutic Gene Editing With CRISPR/Cas9

TJ Cradick , Ph.D., Head of Genome Editing, CRISPR Therapeutics

9:10 Towards Combinatorial Drug Discovery: Mining Heterogenous Phenotypes from Large Scale RNAi/Drug Perturbations

Arvind Rao, Ph.D., Assistant Professor, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center

10:25 CRISPR in Stem Cell Models of Eye Disease

Alexander Bassuk, M.D., Ph.D., Associate Professor of Pediatrics, Department of Molecular and Cellular Biology, University of Iowa

10:55 CRISPR in Mouse Models of Eye Disease

Vinit Mahajan, M.D., Ph.D., Assistant Professor of Ophthalmology and Visual Sciences, University of Iowa College of Medicine

@nyuniversity

@CRISPRTX

@MDAndersonNews

@uiowa

1:15 PM

2:00 PM

Cindy Crowninshield, RDN, LDN, Conference Director, Cambridge Healthtech Institute

1:15 Open Innovation Partnerships to Bridge the Gap from GWAS to Drug Targets Jeffrey Barrett, D.Phil., Founding Director, Open Targets; Group Leader, Wellcome Trust Sanger Institute

Aaron Day-Williams, Ph.D., Biogen Scientific Lead, Open Targets; Associate Director and Head, Statistical Genetics, Biogen

2:00 Cell-Penetrating Mini-Proteins Gregory L. Verdine, Ph.D., Erving Professor, Chemistry, Departments of Stem Cell and Regenerative Biology, Chemistry and Chemical Biology, and Molecular and Cellular Biology, Harvard University and Harvard Medical School

#openinnovation

#openscience

#bioinformatics

#openinnovation

@Biogen

@HarvardMed

8:30 AM

John Doench, Ph.D., Associate Director, Genetic Perturbation Platform, Broad Institute of Harvard and MIT

8:45 Strategies and Applications Using shRNA and CRISPR Technology for Identification of New Druggable Targets

Donald Apanovitch, Ph.D., Director, Functional Genomics (Oncology), Pfizer Research

9:15 High Throughput Phenotypic Screening in Drug Discovery Using the CRISPR-Cas9 System

Greg Hoffman, Ph.D., Investigator III, Developmental & Molecular Pathways Department, Novartis Institutes for Biomedical Research

9:45 CRISPR Libraries for Functional Genomics: Optimizing On-Target Activity and Avoiding Off-Target Effects

John Doench, Ph.D., Associate Director, Genetic Perturbation Platform, Broad Institute of Harvard and MIT

11:10 A High Throughput Functional Genomics Screening Approach to Identify Modulators of Nonsense-Mediated mRNA Decay to Treat Mendelian Disorders

Madhu Lal-Nag, Ph.D., Group Leader, Trans-NIH RNAi Facility, National Center for Advancing Translational Sciences, National Institutes of Health

11:40 Fas-Mediated Apoptosis Overcomes Resistance to Kras-Silencing in Lung Cancer Cells

Haiwei Mou, Ph.D., Postdoctoral Fellow, Laboratory of Dr. Wen Xue, RNA Therapeutics Institute and Program in Molecular Medicine, University of Massachusetts Medical School

12:10 pm Arrayed CRISPR Screening with Synthetic crRNA Libraries for High-Throughput Loss-of-Function Studies

Louise Baskin, Senior Product Manager, Dharmacon, GE Healthcare

Sept. 22 2016

Paul Diehl, Ph.D., Director, Business Development, Cellecta, Inc.

2:20 PM

2:50 PM

3:30 PM

4:00 PM

Roderick Beijersbergen, Ph.D., Group Leader, Netherlands Cancer Institute and Head, NKI Robotics and Screening Center

2:20 Large Scale CRISPR Screens for Discovery of Genotype Specific Combination Therapies

Roderick Beijersbergen, Ph.D., Group Leader, Netherlands Cancer Institute and Head, NKI Robotics and Screening Center

2:50 GPCR-Mediated cAMP as an Immune Checkpoint in Cancer Identified by RNAi Screening

Tillmann Michels, Head of Research Group, Immune Checkpoint Inhibitors, Department of Interventional Immunology, Regensburg Center for Interventional Immunology; Member, Department of Translational Immunology, German Cancer Research Center

3:30 CRISPR-Based Mutagenesis Approach for Cancer Drug Target Identification

Junwei Shi, Ph.D., Assistant Professor, Department of Cancer Biology, University of Pennsylvania School of Medicine

4:00 Applying Functional Genomics in Mouse Models of Human Cancer

Yejing Ge, Ph.D., Postdoctoral Fellow, Laboratory of Dr. Elaine Fuchs, Department of Mammalian Cell Biology and Development, Rockefeller University

4:30 A CRISPR/Cas9 System to Increase Homologous Recombination Repair

Ciro Bonetti, Ph.D., Postdoctoral Scientist, Laboratory of Dr. Andrea Ventura, Memorial Sloan-Kettering Cancer Center